SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare Conference April 8, 2025 11:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of... Read More

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45 th Annual Health Care Conference March 3, 2025 3:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare Conference March 10, 2025 3:00 p.m. ET – fireside... Read More

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 7 th Annual Evercore HealthCONx Conference December 4, 2024 2:10 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare Conference November 19, 2024 10:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s... Read More

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies Enrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash... Read More

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26 th Annual Global Investment Conference September 10, 2024 12:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the... Read More

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 This press release was... Read More

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO,... Read More

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial (“IST”) of NKX019, Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients... Read More

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally,... Read More

Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a... Read More

SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors. Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana Therapeutics where he oversees the... Read More

Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments Strong balance sheet, bolstered by recent $240.1 million offering, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a... Read More

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare Conference April 9, 2024 1:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual Conference April 15, 2024 1:00 p.m. ET – panel... Read More

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price... Read More

First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019 Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101 2023 year-end cash, cash equivalents and... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences: Cowen Annual Health Care Conference March 6, 2024 9:10 a.m. ET – industry panel discussion Leerink Partners Global Biopharma Conference March 11, 2024 12:00 p.m. ET – fireside... Read More

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition featuring follow-up data from its Phase 1 clinical trial that evaluates NKX101 in patients with relapsed or refractory... Read More

FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune disease NKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven safety profile New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy Partnership with Lupus Therapeutics,... Read More

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences: Stifel Healthcare Conference November 14, 2023 10:55 a.m. ET – fireside chat Evercore ISI HealthCONx Conference November 28, 2023 12:30 p.m. ET – fireside chat A simultaneous... Read More

NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory services and will support... Read More

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable... Read More

NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimen NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024 Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations... Read More

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at an upcoming investor conference: Canaccord Genuity 43 rd Annual Growth Conference August 10, 2023 12:00 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of... Read More

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer. “Alyssa is a results-oriented leader with substantial financial and transaction experience, a proven track record of driving business... Read More

Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine) In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate) 2 CRs with MRD negativity 1... Read More

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX101, its allogeneic, off-the-shelf CAR NK cell therapy candidate engineered to target... Read More

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose in the Phase 1 dose escalation study Data demonstrate potential for redosing of allogeneic CD19 CAR NK to deepen response or restore response post-relapse Majority of patients achieved CR after a single cycle of NKX019 Early safety data support potential of... Read More

Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 Cash and cash equivalents of $332.1 million on March 31, 2023 Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell... Read More

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc . (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17 th... Read More

Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO use for clinical applications Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell... Read More

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22 nd Annual Needham Virtual Healthcare Conference April 17, 2023 3:00 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual Conference April... Read More

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief... Read More

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 2022 year-end cash and cash equivalents of $354.9 million Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported... Read More

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: SVB Securities Global Biopharma Conference February 14, 2023 3:40 p.m. ET – fireside chat H.C. Wainwright Cell Therapy Virtual Conference February 28, 2023 Time... Read More

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and... Read More

7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate) 5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cycles Patients with CR observed across multiple NHL histologies, including LBCL Consolidation dosing administered to 7 patients with CRs... Read More

Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company’s platform for engineered CAR NK cell therapy candidates Additional NKX101 and NKX019 clinical data expected by year-end 2022; data expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and... Read More

Ralph Brandenberger, PhD, promoted to Chief Technical Officer Yvonne Li, MBA, promoted to Chief Administrative Officer Evolution of Nkarta leadership team to support rapid development of allogeneic, off-the-shelf NK cell therapies Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotions of Ralph... Read More

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference: Cowen 3rd Annual Oncology Innovation Summit June 2, 2022 11:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com , and a replay will be... Read More

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr. Shook is a practicing pediatric hematologist, oncologist, and transplanter, and an early pioneer of natural killer (NK) cell therapy. He currently directs Nkarta’s co-lead clinical... Read More

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery; MRD negativity in 2 of 3 complete responses Positive preliminary data reported from NKX019 Phase 1 study in patients with relapsed / refractory NHL; 5 of 6 patients treated with a... Read More

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share, and the exercise in full by the underwriters of their option to purchase an additional 2,000,000 shares of common stock. The... Read More

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $15.00 per share. The Company has granted the underwriters a 30-day option to purchase up to 2,000,000 additional shares of its common stock at the public offering price,... Read More